Back to Search
Start Over
Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis.
- Source :
-
Scientific reports [Sci Rep] 2019 Nov 21; Vol. 9 (1), pp. 17309. Date of Electronic Publication: 2019 Nov 21. - Publication Year :
- 2019
-
Abstract
- Neurodegeneration in multiple sclerosis (MS) correlates with disease progression and reparative processes may be triggered. Growth-associated protein 43 (GAP-43) exhibits induced expression during axonal growth and reduced expression during MS progression. We aimed to evaluate if GAP-43 can serve as a biomarker of regeneration in relapsing-remitting MS (RRMS) and whether disease-modifying therapies (DMTs) influence GAP-43 concentration in cerebrospinal fluid (CSF). GAP-43 was measured using an enzyme-linked immunosorbent assay in 105 MS patients (73 RRMS, 12 primary progressive MS, 20 secondary progressive MS) and 23 healthy controls (HCs). In 35 of the patients, lumbar puncture, clinical assessment, and magnetic resonance imaging was performed before initiation of therapeutic intervention, and at follow-up. CSF GAP-43 concentration was significantly lower in progressive MS compared with HCs (p = 0.004) and RRMS (p = < 0.001) and correlated negatively with disability (p = 0.026). However, DMTs did not alter CSF GAP-43. Interestingly, in RRMS CSF GAP-43 levels were higher in patients with signs of active inflammatory disease than in patients in remission (p = 0.042). According to CSF GAP-43 concentrations, regeneration seems reduced in progressive MS, increased during disease activity in RRMS but is unaffected by treatment of highly active DMTs.
- Subjects :
- Adult
Biomarkers cerebrospinal fluid
Case-Control Studies
Disease Progression
Enzyme-Linked Immunosorbent Assay
Female
Follow-Up Studies
GAP-43 Protein immunology
Healthy Volunteers
Humans
Male
Multiple Sclerosis, Chronic Progressive cerebrospinal fluid
Multiple Sclerosis, Chronic Progressive immunology
Multiple Sclerosis, Chronic Progressive therapy
Multiple Sclerosis, Relapsing-Remitting cerebrospinal fluid
Multiple Sclerosis, Relapsing-Remitting immunology
Multiple Sclerosis, Relapsing-Remitting therapy
Treatment Outcome
Young Adult
GAP-43 Protein cerebrospinal fluid
Multiple Sclerosis, Chronic Progressive diagnosis
Multiple Sclerosis, Relapsing-Remitting diagnosis
Nerve Regeneration immunology
Subjects
Details
- Language :
- English
- ISSN :
- 2045-2322
- Volume :
- 9
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Scientific reports
- Publication Type :
- Academic Journal
- Accession number :
- 31754174
- Full Text :
- https://doi.org/10.1038/s41598-019-54032-1